Abstract
Current evidence suggests that functional status is an important outcome of pharmacologic treatments in older people. At the moment, studies have shown diverse effects of medications on functional status. For example, some have shown potentially detrimental effects, while others have found improvements on physical function in elders. Overall, suboptimal prescribing and the occurrence of adverse drug reactions (ADRs) may negatively affect functional status. The use of selected drugs acting on central nervous system (CNS), e.g. benzodiazepines and antipsychotics, is generally associated with an increased risk of functional decline. The greater sensitivity of older people to these drugs, together with age-related changes in pharmacokinetics and pharmacodynamics, account for the observed detrimental effect and suggests a cautious approach to older and frail patients when prescribing CNS agents. On the other hand, selected drugs may slow or delay functional decline in older people. In particular, drugs aimed at targeting sarcopenia (loss in muscle mass and strength), such as testosterone in androgen deficiency, ACE-inhibitors, vitamin D and β-hydroxy β-methyl butyrate (HMB), as well as the recently developed selective androgen receptor modulators (SARMs) may hold extreme importance. This review will provide available evidence of the diverse impacts of drug medications on functional status in older persons.
Keywords: Functional status, adverse drug reactions, ACE inhibitors, CNS agents, sarcopenia, metabolic agents, CNS drugs, hormones, cardiovascular drugs.
Current Pharmaceutical Design
Title:Medications Affecting Functional Status in Older Persons
Volume: 20 Issue: 19
Author(s): Andrea Corsonello, Graziano Onder, Marcello Maggio, Francesco Corica and Fabrizia Lattanzio
Affiliation:
Keywords: Functional status, adverse drug reactions, ACE inhibitors, CNS agents, sarcopenia, metabolic agents, CNS drugs, hormones, cardiovascular drugs.
Abstract: Current evidence suggests that functional status is an important outcome of pharmacologic treatments in older people. At the moment, studies have shown diverse effects of medications on functional status. For example, some have shown potentially detrimental effects, while others have found improvements on physical function in elders. Overall, suboptimal prescribing and the occurrence of adverse drug reactions (ADRs) may negatively affect functional status. The use of selected drugs acting on central nervous system (CNS), e.g. benzodiazepines and antipsychotics, is generally associated with an increased risk of functional decline. The greater sensitivity of older people to these drugs, together with age-related changes in pharmacokinetics and pharmacodynamics, account for the observed detrimental effect and suggests a cautious approach to older and frail patients when prescribing CNS agents. On the other hand, selected drugs may slow or delay functional decline in older people. In particular, drugs aimed at targeting sarcopenia (loss in muscle mass and strength), such as testosterone in androgen deficiency, ACE-inhibitors, vitamin D and β-hydroxy β-methyl butyrate (HMB), as well as the recently developed selective androgen receptor modulators (SARMs) may hold extreme importance. This review will provide available evidence of the diverse impacts of drug medications on functional status in older persons.
Export Options
About this article
Cite this article as:
Corsonello Andrea, Onder Graziano, Maggio Marcello, Corica Francesco and Lattanzio Fabrizia, Medications Affecting Functional Status in Older Persons, Current Pharmaceutical Design 2014; 20 (19) . https://dx.doi.org/10.2174/13816128113196660695
DOI https://dx.doi.org/10.2174/13816128113196660695 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytotoxicity of Anchusa arvensis Against HepG-2 Cell Lines: Mechanistic and Computational Approaches
Current Topics in Medicinal Chemistry Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy
Current Vascular Pharmacology Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Management of Hypertension in Patients with Aortic Valvular Stenosis
Current Hypertension Reviews COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Safety Assessment and Potential Risks of the Glucagon Stimulation Test in the Diagnosis of Secondary Adrenal Insufficiency
Current Drug Safety Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
Infectious Disorders - Drug Targets Editorial (Thematic Issue: Biological Toxins and Medicinal Chemistry: Research and Therapeutic Tools)
Current Topics in Medicinal Chemistry Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Introduction to the Special Issue “Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence” and a Summary of Patents Targeting other Neurotransmitter Systems
Recent Patents on CNS Drug Discovery (Discontinued) Stress Echocardiography
Current Pharmaceutical Design Phytochemical and Pharmacological Insight on Sesamol: An Updated Review
Current Bioactive Compounds Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets